NK010 / Shanghai NK CellTech - LARVOL DELTA

NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Guangzhou Medical University

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Nkaisai NK010 injection has been approved by the U.S. FDA for new drug clinical trials [Google translation] (PRNewswire-Asia) - "On January 17, 2024, a non-genetically modified natural killer cell injection (project code NK010) was independently developed by Shanghai Enkai Cell Technology Co., Ltd. (Enkaisai Pharmaceuticals) ) obtained Phase I clinical trial (IND) approval from the U.S. Food and Drug Administration (FDA)....The first choice for this Phase I clinical trial is ovarian cancer. Preclinical studies have shown that NK010 cell injection exhibits strong anti-tumor activity in solid tumors such as ovarian cancer and liver cancer, as well as animal models such as acute myeloid leukemia."

IND • New P1 trial • Preclinical • Acute Myelogenous Leukemia • Gynecologic Cancers • Hematological Malignancies • Oncology • Ovarian Cancer • Solid Tumor